KLRS vs ADMA vs GRFS vs REPL vs KO

For growth investors, ADMA Biologics, Inc.

(ADMA) is the stronger pick with 19. 6% revenue growth year-over-year, versus 0. 2% for Grifols, S. A. (GRFS). Grifols, S. A. (GRFS) offers the better valuation at 11. 6x trailing P/E (8. 9x forward), making it the more compelling value choice. Analysts rate ADMA Biologics, Inc. (ADMA) a "Buy" — based on 10 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

On trailing P/E, Grifols, S.

A. (GRFS) is the cheapest at 11. 6x versus The Coca-Cola Company at 27. 2x. On forward P/E, Grifols, S. A. is actually cheaper at 8. 9x.

Over the past 5 years, ADMA Biologics, Inc.

(ADMA) delivered a total return of +346. 2%, compared to -74. 4% for Replimune Group, Inc. (REPL). Over 10 years, the gap is even starker: KO returned +121. 1% versus KLRS's -52. 5%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), The Coca-Cola Company (KO) is the lower-risk stock at -0.

20β versus ADMA Biologics, Inc. 's 1. 11β — meaning ADMA is approximately -656% more volatile than KO relative to the S&P 500. On balance sheet safety, Kalaris Therapeutics Inc (KLRS) carries a lower debt/equity ratio of 2% versus 133% for The Coca-Cola Company — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), ADMA Biologics, Inc.

(ADMA) is pulling ahead at 19. 6% versus 0. 2% for Grifols, S. A. (GRFS). On earnings-per-share growth, the picture is similar: Grifols, S. A. grew EPS 147. 8% year-over-year, compared to -25. 9% for ADMA Biologics, Inc.. Over a 3-year CAGR, ADMA leads at 49. 0% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

ADMA Biologics, Inc.

(ADMA) is the more profitable company, earning 28. 8% net margin versus 0. 0% for Replimune Group, Inc. — meaning it keeps 28. 8% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: ADMA leads at 37. 5% versus 0. 0% for REPL. At the gross margin level — before operating expenses — KO leads at 61. 6%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

On forward earnings alone, Grifols, S.

A. (GRFS) trades at 8. 9x forward P/E versus 25. 3x for The Coca-Cola Company — 16. 3x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for KLRS: 331. 2% to $18. 67.

In this comparison, GRFS (2.

7% yield), KO (2. 5% yield) pay a dividend. KLRS, ADMA, REPL do not pay a meaningful dividend and should not be held primarily for income.

For long-horizon retirement investors, The Coca-Cola Company (KO) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β -0.

20), 2. 5% yield, +121. 1% 10Y return). Both have compounded well over 10 years (KO: +121. 1%, ADMA: +15. 3%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

These companies operate in different sectors (KLRS (Healthcare) and ADMA (Healthcare) and GRFS (Healthcare) and REPL (Healthcare) and KO (Consumer Defensive)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced.

In terms of investment character: KLRS is a small-cap quality compounder stock; ADMA is a small-cap high-growth stock; GRFS is a small-cap deep-value stock; REPL is a small-cap quality compounder stock; KO is a large-cap quality compounder stock. GRFS, KO pay a dividend while KLRS, ADMA, REPL do not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.